Biliary Tract Cancer

Common Name(s)

Biliary Tract Cancer

Bile Tract Cancer is a rare digestive cancer characterized by abnormal cell growth in the bile ducts and gallbladder. Individuals with this disorder may grow harmful tumors that can spread to the rest of the body if not diagnosed early. The bile duct system is responsible for storing and transporting bile from the liver, where it is made, to the intestines, where it helps to digest food. Incomplete development of the ducts inhibits the flow of bile. Individuals with this defect have digestion problems as well as a yellow discoloration of the eye and skin (jaundice). Doctors are usually able to diagnose this defect early in the abnormal growth process, as the resulting symptoms are quickly apparent. Treatment is developed on a case-by-case basis and depends on the specific needs of the patient. For prevention measures, digestion specialists may suggest individuals eat a lower-fat diet, or undergo surgery to relieve the blockage or create a tube to allow bile to reach the digestive system. If an individual's cancer has progressed, doctors may suggest chemotherapy to combat cancer symptoms.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Biliary Tract Cancer" returned 104 free, full-text research articles on human participants. First 3 results:

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.
 

Author(s): Caterina Peraldo-Neia, Giuliana Cavalloni, Marco Soster, Loretta Gammaitoni, Serena Marchiò, Francesco Sassi, Livio Trusolino, Andrea Bertotti, Enzo Medico, Lorenzo Capussotti, Massimo Aglietta, Francesco Leone

Journal:

 

Standard chemotherapy in unresectable biliary tract carcinoma (BTC) patients is based on gemcitabine combined with platinum derivatives. However, primary or acquired resistance is inevitable and no second-line chemotherapy is demonstrated to be effective. Thus, there is an urgent ...

Last Updated: 16 Dec 2014

Go To URL
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
 

Author(s): M Moehler, A Maderer, C Schimanski, S Kanzler, U Denzer, F T Kolligs, M P Ebert, A Distelrath, M Geissler, J Trojan, M Schütz, L Berie, C Sauvigny, F Lammert, A Lohse, M M Dollinger, U Lindig, E M Duerr, N Lubomierski, S Zimmermann, D Wachtlin, A-K Kaiser, S Schadmand-Fischer, P R Galle, M Woerns,

Journal: Eur. J. Cancer. 2014 Dec;50(18):3125-35.

 

Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study.

Last Updated: 3 Dec 2014

Go To URL
A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer.
 

Author(s): M G Keane, L Horsfall, G Rait, S P Pereira

Journal:

 

Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTC) are often diagnosed late and at an advanced stage. Population-based screening programmes do not exist and diagnosis is primarily dependent on symptom recognition. Recently symptom-based cancer decision support ...

Last Updated: 21 Nov 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Biliary Tract Cancer" returned 5 free, full-text review articles on human participants. First 3 results:

Current status of chemotherapy for the treatment of advanced biliary tract cancer.
 

Author(s): Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Kazuhiko Koike

Journal: Korean J. Intern. Med.. 2013 Sep;28(5):515-24.

 

Chemotherapy is indispensable for the treatment of advanced biliary tract cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine ...

Last Updated: 6 Sep 2013

Go To URL
Current status of immunotherapy for the treatment of biliary tract cancer.
 

Author(s): Ryuji Takahashi, Munehiro Yoshitomi, Shigeru Yutani, Takahisa Shirahama, Masanori Noguchi, Akira Yamada, Kyogo Itoh, Tetsuro Sasada

Journal: Hum Vaccin Immunother. 2013 May;9(5):1069-72.

 

Biliary tract cancer (BTC) is one of the most aggressive malignancies. Although various promising regimens of chemotherapeutic and/or molecular targeted agents have been developed, further treatment modalities, including immunotherapies, still remain to be established for refractory ...

Last Updated: 7 Oct 2013

Go To URL
Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.
 

Author(s): J R A Skipworth, S W M Olde Damink, C Imber, J Bridgewater, S P Pereira, M Malagó

Journal: Aliment. Pharmacol. Ther.. 2011 Nov;34(9):1063-78.

 

The majority of patients with cholangiocarcinoma present with advanced, irresectable tumours associated with poor prognosis. The incidence and mortality rates associated with cholangiocarcinoma continue to rise, mandating the development of novel strategies for early detection, improved ...

Last Updated: 10 Oct 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Second Line Therapy in Advanced Biliary Tract Cancer
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 9 Feb 2012

Go to URL
Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)
 

Status: Not yet recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 11 Aug 2010

Go to URL
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Ampullary Cancer

 

Last Updated: 13 Jan 2015

Go to URL